TIGEN
LIVE

Serial Number

79311144

Owner

Tigen Pharma SA

Attorney

Stacey Halpern

Filing Date

Feb 4, 2021

Add to watchlist:

No watchlists yet
View on USPTO

TIGEN Trademark

Serial Number: 79311144 • Registration: 7691049

TIGEN is a trademark filed by Tigen Pharma SA on February 4, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Tigen Pharma SA (3 trademarks)

voie du Chariot 3

Entity Type: 33

Trademark Details

Filing Date

February 4, 2021

Registration Date

February 18, 2025

Published for Opposition

February 15, 2022

Goods & Services

Pharmaceutical products and medical preparations, namely, gene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseases, genetic diseases, autoimmune diseases and infectious diseases

Chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in industry and science; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in the development being the manufacture, and manufacture of reagents for industrial or scientific use; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides or proteins, for use of laboratories, diagnostics and analyses for industrial or scientific use; chemical, biochemical, biological and biotechnological substances, namely, polypeptides and proteins, for use in the manufacture of pharmaceuticals * ; all the above-mentioned goods exclusively for use in the fields of anti-cancer therapies and other cell and/or genetic therapies, except emulsifiers *

Medical services; pharmacy advice services, namely, pharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists

Medical instruments, equipment and apparatus, namely, instruments, equipment and apparatus for cell and cell material collection, thawing, washing, selection, expansion, modification, harvesting, final formulation, freezing, storage and infusion into a patient in the fields of genetic diseases, autoimmune diseases, infectious diseases, localized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions

Scientific research, technological development of new products for third parties; medical research; scientific and industrial research in biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific services, namely, development of medicines, active substances and vaccines; scientific services, namely, development of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; upgrading, maintenance and rental of computer software; updating, maintenance and rental of computer software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process development, manufacturing, quality, and supply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; chemical and biological laboratory services

Filing History

NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Sep 23, 2025 NURC
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 19, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 2, 2025 FICS
LIMITATION FROM THE IB EXAMINED AND ENTERED
Sep 2, 2025 LIME
FINAL DISPOSITION PROCESSED
Sep 2, 2025 FIMP
CORRECTION UNDER SECTION 7 - PROCESSED
Sep 2, 2025 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 2, 2025 APRE
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Aug 29, 2025 LIMN
LIMITATION OF GOODS RECEIVED FROM IB
Jun 13, 2025 LIMG
LIMITATION OF GOODS RECEIVED FROM IB
Jun 6, 2025 LIMG
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 18, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 18, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 18, 2025 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Jan 29, 2025 TMBN
OPPOSITION TERMINATED NO. 999999
Jan 29, 2025 OP.T
OPPOSITION DISMISSED NO. 999999
Jan 29, 2025 OP.D
NEW REPRESENTATIVE AT IB RECEIVED
Dec 31, 2023 NREP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 11, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 8, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 8, 2023 OPNR
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Aug 2, 2022 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Jun 5, 2022 CRCV
REFUSAL PROCESSED BY IB
Apr 10, 2022 RFNT
OPPOSITION INSTITUTED NO. 999999
Mar 28, 2022 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Mar 16, 2022 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Mar 16, 2022 OPNC
OPPOSITION PAPERS RECEIVED AT TTAB
Mar 15, 2022 OPPF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 15, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 14, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 26, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 26, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 26, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 11, 2022 PREV
ASSIGNED TO LIE
Jan 11, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 10, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 10, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 10, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 10, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 10, 2022 CNEA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 7, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 7, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 7, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 7, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 7, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 7, 2022 COAR
REFUSAL PROCESSED BY IB
Oct 4, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 14, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 14, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 14, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 13, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 27, 2021 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Aug 20, 2021 NREP
APPLICATION FILING RECEIPT MAILED
May 25, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 20, 2021 REPR